CoChat

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

Open access
Stanczak, Michal A., Rodrigues Mantuano, Natalia, Kirchhammer, Nicole, Sanin, David E., Jacob, Francis, Coelho, Ricardo, Everest-Dass, Arun V., Wang, Jinyu, Trefny, Marcel P., Monaco, Gianni, Bärenwaldt, Anne, Gray, Melissa A., Petrone, Adam, Kashyap, Abhishek S., Glatz, Katharina, Kasenda, Benjamin, Normington, Karl, Broderick, James, Peng, Li, Pearce, Oliver M.T., Pearce, Erika L., Bertozzi, Carolyn R., Zippelius, Alfred, Läubli, Heinz · 2022 · Science Translational Medicine
Cited by 243

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Immune checkpoint blockade (ICB) has substantially improved the prognosis of patients with cancer, but the majority experiences limited benefit, supporting the need for new therapeutic approaches. Up-regulation of sialic acid–containing glycans, termed hypersialylation, is a common feature of cancer-associated glycosylation, driving disease progression and immune escape through the engagement of Siglec receptors on tumor-infiltrating immune cells. Here, we show that tumor sialylation correlates with distinct immune states and reduced survival in human cancers. The targeted removal of Siglec ligands in the tumor microenvironment, using an antibody-sialidase conjugate, enhanced antitumor immunity and halted tumor progression in several murine models. Using single-cell RNA sequencing, we revealed that desialylation repolarized tumor-associated macrophages (TAMs). We also identified Siglec-E as the main receptor for hypersialylation on TAMs. Last, we found that genetic and therapeutic desialylation, as well as loss of Siglec-E, enhanced the efficacy of ICB. Thus, therapeutic desialylation represents an immunotherapeutic approach to reshape macrophage phenotypes and augment the adaptive antitumor immune response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abj1270

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 243

Metadata

Authors
Stanczak, M. A., Rodrigues Mantuano, N., Kirchhammer, N., Sanin, D. E., Jacob, F., Coelho, R., Everest-Dass, A. V., Wang, J., Trefny, M. P., Monaco, G., Bärenwaldt, A., Gray, M. A., Petrone, A., Kashyap, A. S., Glatz, K., Kasenda, B., Normington, K., Broderick, J., Peng, L., Pearce, O. M. T., Pearce, E. L., Bertozzi, C. R., Zippelius, A., & Läubli, H.
Venue
Science Translational Medicine
Published
2022-11-02
Volume
14
Issue
669
Pages
eabj1270-eabj1270
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W4307930338
Cited by
243
References
14
FWCI
14.02
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. https://app.cochat.ai/papers/10.1126/scitranslmed.abj1270
The paper
Stanczak, M. A., Rodrigues Mantuano, N., Kirchhammer, N., Sanin, D. E., Jacob, F., Coelho, R., Everest-Dass, A. V., Wang, J., Trefny, M. P., Monaco, G., Bärenwaldt, A., Gray, M. A., Petrone, A., Kashyap, A. S., Glatz, K., Kasenda, B., Normington, K., Broderick, J., Peng, L., . . . Läubli, H. (2022). Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abj1270

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.